AR087365A1 - Farmaco a base de levomilnacipran para la recuperacion funcional luego de eventos neurologicos agudos - Google Patents

Farmaco a base de levomilnacipran para la recuperacion funcional luego de eventos neurologicos agudos

Info

Publication number
AR087365A1
AR087365A1 ARP120102747A ARP120102747A AR087365A1 AR 087365 A1 AR087365 A1 AR 087365A1 AR P120102747 A ARP120102747 A AR P120102747A AR P120102747 A ARP120102747 A AR P120102747A AR 087365 A1 AR087365 A1 AR 087365A1
Authority
AR
Argentina
Prior art keywords
levomilnacipran
functional recovery
pharmaco
dextromilnacipran
neurological events
Prior art date
Application number
ARP120102747A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR087365A1 publication Critical patent/AR087365A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de Ievomilnacipran como producto medicinal en la recuperación funcional luego de un accidente cerebrovascular o una lesión cerebral traumática. Las composiciones farmacéuticas que contienen levomilnacipran son exclusivamente aquellas que no contienen dextromilnacipran en una proporción superior al 5% en peso de la mezcla de levomilnacipran/dextromilnacipran, a fin de evitar comprometer la recuperación funcional debido a la propiedad a1-bloqueante del dextromilnacipran.
ARP120102747A 2011-07-28 2012-07-27 Farmaco a base de levomilnacipran para la recuperacion funcional luego de eventos neurologicos agudos AR087365A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1156917A FR2978350B1 (fr) 2011-07-28 2011-07-28 Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu

Publications (1)

Publication Number Publication Date
AR087365A1 true AR087365A1 (es) 2014-03-19

Family

ID=46598516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102747A AR087365A1 (es) 2011-07-28 2012-07-27 Farmaco a base de levomilnacipran para la recuperacion funcional luego de eventos neurologicos agudos

Country Status (17)

Country Link
US (1) US20140179794A1 (es)
EP (1) EP2736503B1 (es)
JP (1) JP2014521627A (es)
KR (1) KR20140050668A (es)
CN (1) CN103702666A (es)
AR (1) AR087365A1 (es)
AU (1) AU2012288808A1 (es)
BR (1) BR112014001961A2 (es)
CA (1) CA2843037A1 (es)
FR (1) FR2978350B1 (es)
IL (1) IL230642A0 (es)
MA (1) MA35418B1 (es)
MX (1) MX2014001028A (es)
RU (1) RU2014106661A (es)
TN (1) TN2014000032A1 (es)
TW (1) TW201311232A (es)
WO (1) WO2013014263A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
AU2003213009A1 (en) 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030203055A1 (en) 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
CN1662231A (zh) 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
MXPA05000566A (es) 2002-07-24 2005-08-29 Cypress Bioscience Inc Tratamiento de depresion secundaria al dolor (dsp).
AU2003284005B2 (en) 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
WO2004045718A2 (en) 2002-11-20 2004-06-03 Cypress Bioscience, Inc. Treatment of cognitive dysfunctions'
WO2004075886A1 (fr) * 2003-02-14 2004-09-10 Pierre Fabre Medicament Utilisation de l’enantiomere (1s, 2r) du milnacipran pour la preparation d’un medicament
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
AU2005260955A1 (en) 2004-07-14 2006-01-19 Astellas Pharma Inc. Agent for promoting the recovery from dysfunction after the onset of central neurological disease
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080058318A1 (en) 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
US20080058317A1 (en) 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
TW200911225A (en) 2007-05-22 2009-03-16 Cypress Bioscience Inc Methods for improving physical function in fibromyalgia
EP2110129A1 (en) 2008-04-18 2009-10-21 Pierre Fabre Medicament Use of enantiomer (1S, 2R) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
CA2790933A1 (en) * 2010-01-14 2011-07-21 Forest Laboratories Holdings Limited Stable dosage forms of levomilnacipran

Also Published As

Publication number Publication date
FR2978350B1 (fr) 2013-11-08
MX2014001028A (es) 2014-03-27
TW201311232A (zh) 2013-03-16
US20140179794A1 (en) 2014-06-26
MA35418B1 (fr) 2014-09-01
RU2014106661A (ru) 2015-09-10
CA2843037A1 (fr) 2013-01-31
WO2013014263A1 (fr) 2013-01-31
EP2736503A1 (fr) 2014-06-04
EP2736503B1 (fr) 2015-07-08
NZ621474A (en) 2015-02-27
BR112014001961A2 (pt) 2017-02-21
TN2014000032A1 (fr) 2015-07-01
JP2014521627A (ja) 2014-08-28
AU2012288808A1 (en) 2014-03-13
IL230642A0 (en) 2014-03-31
FR2978350A1 (fr) 2013-02-01
KR20140050668A (ko) 2014-04-29
CN103702666A (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
DOP2017000261A (es) Derivados de ciclohexano sustituido con amido
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CR20160033A (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromático-bencil-amida
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
NI201500050A (es) Benzamidas
BR112014013085A2 (pt) forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
DOP2020000072A (es) Amidas de imidazopiridina sustituidas y su uso
UY37193A (es) Nuevos compuestos antivíricos
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
PA8806801A1 (es) Compuestos de amida como refuerzos de antivirales
PH12015502747A1 (en) Novel compounds for the treatment of cancer
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt

Legal Events

Date Code Title Description
FB Suspension of granting procedure